Alnylam Pharmaceuticals and Tenaya Therapeutics have agreed a research collaboration to discover novel human genetic targets for the potential development of disease-modifying treatments for cardiovascular diseases. Under the terms of the agreement, Tenaya Therapeutics will validate up to 15 gene targets. In return, Tenaya will receive up to $10 million in the form of an […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!